Physician profile
Nancy Smith
NPI 1326338542
$10,343.06
in general payments reported to CMS, 2019-2025
26 companies · $3,097 in 2025
The $3,097 reported for 2025 was more than what 97% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,421 · 2022: $1,869 · 2023: $1,952 · 2024: $2,004 · 2025: $3,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,878 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,878.22 |
| Education | $174.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,266.93 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,306.70 | 2021-2025 | |
| Genzyme Corporation | $1,236.23 | 2021-2025 | |
| Lilly USA, LLC | $825.32 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Janssen Biotech, INC. | $819.71 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Leo Pharma INC. | $657.07 | 2022-2025 | Anzupgo, Adbry |
| Sun Pharmaceutical Industries INC. | $567.81 | 2021-2025 | Odomzo, Blu-U, Winlevi |
| Regeneron Healthcare Solutions, INC. | $535.44 | 2022-2025 | Dupixent, Libtayo |
| Ucb, INC. | $404.59 | 2023-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $378.54 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Amgen INC. | $335.42 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $206.70 | 2022-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $176.20 | 2021-2025 | |
| Almirall LLC | $143.85 | 2021-2025 | Klisyri, Seysara |
| E.R. Squibb & Sons, L.L.C. | $141.56 | 2022-2025 | Sotyktu, Sprycel |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $75.33 | 2022-2025 | Cabtreo, Arazlo |
| Dermavant Sciences, INC. | $47.76 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.79 | 2023-2024 | Cyltezo |
| Pfizer INC. | $44.72 | 2022-2023 | |
| Botanix Sb INC | $30.35 | 2025 | Sofdra |
| Aurinia Pharma U.S., INC. | $24.15 | 2022 | |
| Paratek Pharmaceuticals, INC. | $20.32 | 2025 | Nuzyra |
| Glaxosmithkline, LLC. | $15.98 | 2023 | Jesduvroq, Benlysta |
| Kyowa Kirin, INC. | $15.85 | 2024 | Poteligeo |
| Journey Medical Corporation | $12.72 | 2022 | |
| Organon LLC | $9.02 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.